Related Experiment Video
Updated: Dec 23, 2025
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic
1Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Insights
Targeted therapies for chronic lymphocytic leukemia (CLL) impact the immune system, potentially affecting treatment response. Combination therapies may overcome these effects and restore immune activity.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) involves immune tolerance due to interactions between CLL cells and immune components.
- Novel targeted therapies are crucial in CLL treatment but can disrupt the immune environment.
- Pre-existing immune dysfunction in CLL is exacerbated by these targeted therapies.
Purpose of the Study:
- To review the immune dysfunction in CLL.
- To analyze the impact of targeted therapies on the CLL immune milieu.
- To explore combination therapy strategies to enhance treatment outcomes.
Main Methods:
- Literature review of immune dysfunction in CLL.
- Analysis of targeted therapy effects on immune cells in CLL.
- Evaluation of combination therapy approaches in CLL.
Main Results:
- Targeted therapies can have dual effects, promoting both anti- and pro-cancer activity.
- This dual action may limit the depth and duration of therapeutic response.
- Immune system perturbations are a significant factor in CLL treatment efficacy.
Conclusions:
- Combination therapies show promise in mitigating adverse immune effects of targeted treatments.
- Strategic combination approaches may improve treatment response duration in CLL.
- Restoring immune activity is a key goal for enhancing CLL therapy.
Abstract:
A complex interplay between chronic lymphocytic leukemia (CLL) cells and different constituents of the immune system generally results in immune tolerance. As targeted therapies are gaining a critical role in the therapeutic landscape of this disease, their impact on the already perturbed immune milieu needs to be considered. This review addresses the issues of basic immune dysfunction in CLL which is further complicated by the effects of a number of novel targeted therapies used for this malignancy. These new approaches may simultaneously facilitate both anti- and pro-cancer activity, potentially compromising the depth of response to therapy. Current evidence suggests that exploiting combination therapy could potentially overcome at least part of these deleterious effects, thereby prolonging response to treatment and helping to restore immune activity.
More Related Videos
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...